Schizophrenia Clinical Trials in Boston, Massachusetts

13 studies are recruiting for schizophrenia in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

   The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

   Stage

   Phase 3

   Ages

   13 to 17

   Site

   Boston Children's Hospital, Boston, Massachusetts

   Locations

   38 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07288567 on ClinicalTrials.gov

2. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Boston, Massachusetts

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

3. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

   The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Boston Children's Hospital, Boston, Massachusetts

   Locations

   91 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07424404 on ClinicalTrials.gov

4. Cerebellar Modulation of Cognition in Psychosis

   The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to answer is: Can we use magnetic stimulation to change processing speed (how quickly people can solve challenging tasks). Pa…

   Stage

   Not phased

   Ages

   18 to 55

   Site

   Beth Israel Deaconess Medical Center, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Mclean Hospital

   See if you can join NCT06107764 on ClinicalTrials.gov

5. Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

   The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

   Stage

   Not phased

   Ages

   18 and older

   Site

   Boston Medical Center, Boston, Massachusetts

   Locations

   20 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07101094 on ClinicalTrials.gov

6. Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

   Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Brigham and Women's Hospital

   See if you can join NCT06376734 on ClinicalTrials.gov

7. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

   This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, Boston, Massachusetts

   Locations

   57 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07114874 on ClinicalTrials.gov

8. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

   The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, Boston, Massachusetts

   Locations

   20 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07227818 on ClinicalTrials.gov

9. CLOZAPINE Response in Biotype-1

   The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as ps…

   Stage

   Phase 4

   Ages

   18 to 60

   Site

   Beth Israel Deaconess Medical Center, Boston, Massachusetts

   Locations

   5 in total

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT04580134 on ClinicalTrials.gov

10. Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

    The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder. It involves gathering mental health information, brain scans (MRI), eye movement …

    Stage

    Not phased

    Ages

    18 to 40

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Locations

    6 in total

    Run by

    Beth Israel Deaconess Medical Center

    See if you can join NCT06740383 on ClinicalTrials.gov

11. Enhanced Coordinated Specialty Care for Early Psychosis

    The goal of this clinical trial is to compare engagement in treatment in coordinated specialty care (CSC) to five extra care elements (CSC 2.0) in first-episode psychosis. The main question it aims to answer is: • Does the addition of certain elements of care increase the number of visits in treatm…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massachusetts General Hospital FEPP Clinic, Boston, Massachusetts

    Locations

    5 in total

    Run by

    Mclean Hospital

    See if you can join NCT06071858 on ClinicalTrials.gov

12. Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

    In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT04296604 on ClinicalTrials.gov

13. Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

    This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period o…

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Reviva site, Boston, Massachusetts

    Locations

    18 in total

    Run by

    Reviva Pharmaceuticals

    See if you can join NCT05184335 on ClinicalTrials.gov